Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration

Detalles Bibliográficos
Autores principales: Ference, Brian A, Cannon, Christopher P, Landmesser, Ulf, Lüscher, Thomas F, Catapano, Alberico L, Ray, Kausik K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047439/
https://www.ncbi.nlm.nih.gov/pubmed/29020411
http://dx.doi.org/10.1093/eurheartj/ehx450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047439/
https://www.ncbi.nlm.nih.gov/pubmed/29020411
http://dx.doi.org/10.1093/eurheartj/ehx450

Ejemplares similares